MARKET

BCAB

BCAB

Bioatla, Inc.
NASDAQ
3.555
-0.235
-6.20%
Opening 14:43 06/25 EDT
OPEN
3.870
PREV CLOSE
3.790
HIGH
3.905
LOW
3.500
VOLUME
72.99K
TURNOVER
--
52 WEEK HIGH
71.50
52 WEEK LOW
3.120
MARKET CAP
5.90M
P/E (TTM)
-0.0850
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCAB last week (0615-0619)?
Weekly Report · 3d ago
Weekly Report: what happened at BCAB last week (0608-0612)?
Weekly Report · 06/15 09:19
Weekly Report: what happened at BCAB last week (0601-0605)?
Weekly Report · 06/08 09:18
Weekly Report: what happened at BCAB last week (0525-0529)?
Weekly Report · 06/01 09:19
Weekly Report: what happened at BCAB last week (0518-0522)?
Weekly Report · 05/25 09:20
Context Therapeutics Announces Amendment To Its Exclusive License Agreement With BioAtla To Remove All Future Milestone And Royalty Obligations For CT-202 In Exchange For A $4.5M Upfront Payment And A Final $2M Payment Due By August 1
Benzinga · 05/18 10:49
CONTEXT THERAPEUTICS - TO PAY $4.5 MLN UPFRONT AND $2.0 MLN BY AUG 1, 2026 FOR CT-202 LICENSE
Reuters · 05/18 10:45
Weekly Report: what happened at BCAB last week (0511-0515)?
Weekly Report · 05/18 09:20
More
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Webull offers Bioatla Inc stock information, including NASDAQ: BCAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCAB stock methods without spending real money on the virtual paper trading platform.